OmarNadeemMD

Hematologic Oncology

Multiple Myeloma Physician Dana-Farber Cancer Institute

Dr. Nadeem is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Brown UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2009 - 2012
Ross University School of MedicineClass of 2009

DARA RVD For High Risk SMM Start of enrollment: 2021 Mar 08
Recruiting
Phase 2
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Active, not recruiting
Phase 1
Roles: Principal Investigator

PubMed

16 citations
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, mult...
Annie Cowan, Federico Ferrari, Samuel S Freeman, Robert Redd, Habib El-Khoury
The Lancet. Haematology. 2023-03-01
35 citations
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Christopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, Leyla O Shune, Joseph P McGuirk
Blood Cancer Journal. 2023-08-09
16 citations
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Romanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, Joanna Baginska, Nicholas J Haradhvala
Cancer Cell. 2022-11-14

Abstracts/Posters

A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Omar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Omar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Omar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

When Is Treating a Precursor Condition Harmful?October 8th, 2024
Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
Immunotherapeutic and Targeted Approaches in Multiple MyelomaOctober 14th, 2020
Join now to see all